Health and Healthcare
Genentech Mixes Top-Line & Bottom-Line Numbers (DNA)
Published:
Last Updated:
Genentech, Inc. (NYSE: DNA) today posted earnings of $0.81 per share and $3.408 billion in revenue. That’s below First Call estimates of $0.88 on $3.36 billion in revenue. For what this is worth, Genentech noted that earnings were affected by items.
The biotech giant has also noted that guidance for 2008 is now $3.40 to$3.45, rather than its prior guidance of $3.40 to $3.50.
Genentech saidtwo drugs posted year-over-year declines rather than just one drug lastquarter. The good news is that the company did beat on its top-linenumbers and its key drugs Avastin and Rituxan were slightly ahead ofplan.
Unfortunately, it only looks like we’ll get merger data in the conference call because it wasn’t noted in depth here. One issue Genentech has noted is that it filed for FDA approval for its Avastin in kidney cancer which has spread.
Shares of Genentech closed down 2.5% at $79.12 today, and shares are actually trading up about $2.00.
Jon C. Ogg
October 14, 2008
The #1 Thing to Do Before You Claim Social Security (Sponsor)
Choosing the right (or wrong) time to claim Social Security can dramatically change your retirement. So, before making one of the biggest decisions of your financial life, it’s a smart idea to get an extra set of eyes on your complete financial situation.
A financial advisor can help you decide the right Social Security option for you and your family. Finding a qualified financial advisor doesn’t have to be hard. SmartAsset’s free tool matches you with up to three financial advisors who serve your area, and you can interview your advisor matches at no cost to decide which one is right for you.
Click here to match with up to 3 financial pros who would be excited to help you optimize your Social Security outcomes.
Have questions about retirement or personal finance? Email us at [email protected]!
By emailing your questions to 24/7 Wall St., you agree to have them published anonymously on a673b.bigscoots-temp.com.
By submitting your story, you understand and agree that we may use your story, or versions of it, in all media and platforms, including via third parties.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
